Status:
COMPLETED
LDL Receptor Under Ezetimibe and Simvastatin
Lead Sponsor:
University of Cologne
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Healthy Men
Eligibility:
MALE
18-60 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to investigate the effects of the two lipid -lowering drugs, ezetimibe and simvastatin, on lipid metabolism in humans. In specific, the study will investigate in blood cel...
Detailed Description
Ezetimibe decreases serum total and LDL cholesterol levels by blocking cholesterol absorption in the intestine, causing a compensatory increase in cholesterol synthesis. The exact underlying regulator...
Eligibility Criteria
Inclusion
- healthy male subjects
- age between 18 and 60 years
- body mass index between 18.5 and 30 kg/m2
- LDL cholesterol smaller than 190 mg/dL
- triglicerides smaller than 250 mg/dL
- normal blood pressure
Exclusion
- intake of lipid-lowering drugs
- excessive alcohol intake
- liver disease
- kidney disease
- coronary heart disease
- eating disorders
- diabetes or other endocrine disorders
- medications that interfere with lipid metabolism
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
End Date :
July 1 2004
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00317993
Start Date
April 1 2004
End Date
July 1 2004
Last Update
December 3 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medizinische Klinik II und Poliklinik für Innere Medizin
Cologne, Germany, 50924